[Ezetimibe=cost effectiveness. Science or a debate contribution from MSD?].
Lindberg
Mats
M
D000924:Anticholesteremic Agents / Q000191:economics*; D001384:Azetidines / Q000191:economics*; D016265:Conflict of Interest; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D004345:Drug Industry / Q000191:economics; D000069438:Ezetimibe; D006801:Humans
D000924:Anticholesteremic Agents; D001384:Azetidines; D000069438:Ezetimibe